Treatment and prevention of osteoporosis: future directions.
Osteoporosis is an important disease because of its prevalence and because it is associated with significant morbidity and mortality. As a consequence, development of new means of treating the disease is a major goal of drug companies. A number of new scientific discoveries have provided new rationales for development of new drugs that act either to inhibit bone resorption or to stimulate bone formation. These new drugs should greatly expand the therapeutic approach that can be used for treatment of this common disorder in the individual patient.
Bell
N H
NH
Department of Medicine, Medical University of South Carolina, 171 Ashley Ave., Charleston, SC 29425, USA.
Termine
J D
JD
D000818:Animals; D001862:Bone Resorption / Q000503:physiopathology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D016023:Integrins / Q000037:antagonists & inhibitors; D051379:Mice; D010024:Osteoporosis / Q000503:physiopathology / Q000517:prevention & control*; D010281:Parathyroid Hormone / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016023:Integrins; D010281:Parathyroid Hormone; D020845:Selective Estrogen Receptor Modulators